gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:approves
|
gptkb:various_countries
gptkb:1997
|
gptkbp:associated_with
|
risk of stroke
risk of heart attack
|
gptkbp:available_in
|
oral form
|
gptkbp:brand
|
gptkb:Reductil
gptkb:Meridia
|
gptkbp:class
|
anorectic agent
|
gptkbp:clinical_trial
|
weight management studies
|
gptkbp:contraindication
|
gptkb:Cardiology
pregnancy
breastfeeding
eating disorders
history of stroke
|
gptkbp:discontinued
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:New_Zealand
gptkb:United_Kingdom
gptkb:United_States
|
gptkbp:dosage_form
|
10 mg
15 mg
|
gptkbp:duration
|
short-term use
long-term use not recommended
|
gptkbp:formulation
|
gptkb:capsule
|
https://www.w3.org/2000/01/rdf-schema#label
|
Reductil
|
gptkbp:ingredients
|
synthetic compound
sibutramine
|
gptkbp:interacts_with
|
gptkb:beer
MAO inhibitors
other weight loss medications
|
gptkbp:is_monitored_by
|
required during treatment
|
gptkbp:marketed_as
|
gptkb:Abbott_Laboratories
|
gptkbp:mechanism_of_action
|
gptkb:depression
|
gptkbp:regulatory_compliance
|
prescription only
|
gptkbp:related_to
|
obesity treatment
|
gptkbp:replaces
|
gptkb:2010
some markets
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
insomnia
constipation
dry mouth
sweating
increased heart rate
palpitations
|
gptkbp:storage
|
room temperature
dry place
|
gptkbp:suitable_for
|
gptkb:children
adolescents
elderly patients
|
gptkbp:used_for
|
weight loss
|
gptkbp:weight_loss_effect
|
varies by individual
|
gptkbp:bfsParent
|
gptkb:Sibutramine
gptkb:Sibutramine_hydrochloride
|
gptkbp:bfsLayer
|
6
|